Jefferies Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $930
Jefferies analyst Akash Tewari maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $870 to $930.
Share
Why It Matters
An expert thinks Regeneron is worth more money than before. This means the company looks stronger, so keep watching how its medicines are selling.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.